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with no evidence of disease. Flow cytometry shows no aberrant 
populations. Cytogenetic testing is pending at this report. HTLV 
1 viral load studies show consistent decrease in viral load. The 
patient is enjoying an active life with no significant post transplant 
adverse ffects. 
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HOST-REACTIVE MEMORY T LYMPHOCYTES ALONE DO NOT INDUCE 
MORE SEVERE GRAFT-VERSUS-HOST DISEASE 
Chert, B.J.; Cui, X.; C,~ao, N.J. Dltke U, ivevsity Medical Center, 
Din'ham, NC. 
Memo W T lylnphocytes are thought o mediate more rapid and 
profound memory irnmunc response. In this study, we tested 
whether it is true in graft-versus-host disease (GVHD). C57BL/6 
mice (H2 b) were injected with irradiated BALB/c (H2 d) spleen 
cells intraperitoneally at least 8 weeks before they were used as 
immunized onors. Splenic T cells (>90% pure) were harvested 
from these immunized animals and separated into CD62L + (>90% 
pure) and CD62L- (>99% pure) populations by magnetic beads. 
CD62L + T cells include both naive and memory T cells, while 
CD62L- T cells contain memory T cells but no naive T cells. We 
next compared the alloreactivity and the ability to induce GVHD 
(C57BL/6 to BALB/c) of CD62L T cells with those of unseparat- 
ed and CD62L + T cells. Despite CD62L (memory) T cells con- 
tain similar numbers of interferon-y-secreting cells upon response 
to host antigens as detected by enzyme-linked immunospot assay, 
CD62L- T cells had dramatically decreased ability to induce 
GVHD in BALB/e mice compared to unseparated and CD62L + T 
cell controls (Table). However, CD62L T cell recipients did 
develop GVHD as documented by weight loss (Table) and histo- 
logic changes. Similar results were observed when the mice immu 
nized with BCL1 cells (a BALB/c-or igin B cell 
lymphoma/leukelnia cell line) were used as donors. We conclude 
that host-reactive m mm T T cells alone have decreased ability to 
induce GVHD compared with a mixture of naive and memory T
cells. Memory T cells obtained from tumor cel l - immunized 
donors may be a unique source of T cells for tumor imnmnothera- 
py because they do not induce severe GVHD. 
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A CRITICAL ROLE FOR CD4+CD25 ÷ SUPPRESSOR CELLS IN CON- 
TROLLING GVHD AFTER DLI IN MURINE BONE MARROW CHIMERAS 
Xia, G., Yah, X.; Cao, 0.; T77titt, R.L.; Johnson, B.D. Depmv:me,t of 
Pediatrics, ~Iedit:al College of IUisconsi{z, 3/lilwzzkee, ~Z 
A murine model of allogeneic bone marrow (BM) transplanta- 
tion (C57BL/6[B6]-into-AKR/J) was used to further define the 
role of CD4+CD25 * T cells in controling GVHD after DLI and 
their potential  therapeutic application. B6- into-AKR BM 
chimeras were depleted of CD25 + cells in vivo with anti-CD25 
mAb or transplanted with BM from CD25 K° donors so that the 
BM recipients would be devoid of donor-derived CD25 + cells. 
Depletion of CD25 + cells in vivo (>70% depletion) significantly 
increased the severity of DLI- induced GVHD as indicated by 
body weight loss and increased mortality as compared to nonde- 
pleted control mice. GVHD was even more intense in mice trans- 
planted with CD25 k° BM. Enhanced GVHD after CD25 deple- 
tion was seen after DLI of either 30 million or 60 million donor 
splenocytes. To test the ability of CD25 ~ cells to persist and 
expand in vivo, nylon-wool enriched, immunomagnetically select- 
ed fresh CD25 ÷ cells were adoptively transferred into syngeneic 
nude mice. These cells progressively expanded (CD4 and CD8 
subsets) over 5 months in syngeneic nude mice. Approximately 
30% of the cells at 2-wk and less than 10% at 20-wk were still 
CD25 *. Various conditions for activation and expansion of CD25+ 
suppressor cells were examined. Freshly-isolated B6 CD25 ÷ cells 
were cultured with rIL-2 in the presence of (1) immoblized anti- 
CD3 mAb plus soluble anti-CD28 mAb, (2) magnetic beads coat- 
ed with anti-CD3 and anti-CD28 mAbs, and (3) CD32/4-1BB lig- 
and double-transfected K562 tmnor cells (K562DT) "loaded" 
with anti CD3 and anti-CD28 mAbs. The K562DT cells induced 
superior short-term expansion of CD4+CD25+cells (>10 fold after 
7-10 days of culture). Imnmblized anti-CD3 plus soluble anti- 
CD28 preferentially expanded the CD8 subset from <3% in fresh 
CD25+cells to >75% of the total cells after 1 week of culture. Ex 
vivo expanded CD25 ÷ cells were more suppressive than fresh cells 
added to primary mixed lymphocyte cultures in which 50% of 
stimulation inhibition was achieved at a 1:8 CD25*/CD25 ratio 
for ex vivo expanded CD25 + as compared to a 1:1 ratio required 
for fresh cells. Studies looking at the ability of ex vivo expanded 
CD25 + ceils to persist/expand in vivo, and the GVHD-protective 
role of freshly-isolated versus ex vivo expanded CD25" cells coad- 
ministered with DLI, are in progress. 
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TCR TRANSGENIC HEMATOPOETIC STEM CELLS ENGRAFT INTO 
NON-TRANSGENIC RECIPIENTS AND EVOLVE ANTIGEN-SPECIFIC 
T-CELLS 
Krnft, D.L.; Ranheim, E.A.; Weissman, I.L. Pediatric 
Hematology/Oncology and Dept of Pathology, Sta~zfo'rd University 
School of ~/ledicine, Staj~'ord, CA. 
We hypothesized that genetically modified hematopoetic stem 
cells (HSC) transduced with a specific tmnor antigen specific 
TCR may, when given as a fraction of a donor hematopoetic 
sten, cell graft, lead to engraftment of tumor antigen specific T-  
cells and facilitate directed Graft vs Malignancy (GVL). ~¢\7e are 
developing a model system for exploring the feasibility of this 
approach. An important component of evaluating such a strategy 
is determining the ability for donor TCR-transgenic HSC to 
engraft into non-transgenic recipients, and to determine the 
ldneties of antigen specific T-cell  engraftment. P14 mice are 
transgenic for the elass-I restricted TCR specific to LCMV-Gly- 
coprotein-33. Bone marrow was obtained from P14 CD45.2 
TCR-Transgenic mice and transplanted into lethally irradiated 
non-transgenic, ongenic CD45.1 recipients. Of the 500, 000 
marrow cells in the graft, 0%, 10%, 25%, 50% or 100% was 
from a P14 donor, the remainder from CD45.1 congenic mar- 
row. The number of LCMV-GP33 specific T-cells in the periph- 
eral blood was measured weekly with MHC-H-2  D(b)GP33 
tetramer. Control P14 mice contained an average of 25% CD8+ 
cells in the peripheral blood, of which 82% were GP33 tetramer 
positive. We found that TCR-transgenic  P14 bone marrow 
would engraft, and result in measurable donor derived LCMV- 
GP specific CD8+ T-cells. The fraction of tetramer positive T- 
ceils in peripheral blood increased in correlation to the percent- 
age of P 14 bone marrow transplanted. Four weeks post-transplant 
CD45.2, tetramer+ T-cells made up a mean 3.5% of peripheral 
bloo.d in mice which had received 100% P14 donor marrow, 
1.3% from 50% P14 donor, and .63% from a 25% P14 marrow 
donor. By week five, tetramer + cells had increased to 9.4% of 
blood cells in mice receiving 100% P14 donor marrow, 4.7% 
from 50% P14 marrow and .74% from 25% donor. Engraftment 
of tetramer+ T-cel ls increased in weeks 5 and 6 and then 
remained stable. 7 weeks post transplant in mice receiving 50% 
P14 marrow, 8.8% of peripheral cells were CD8+, of which 
43.7% were tetramer+. 25% P14 transgenic donor recipients 
evolved 5.5% CD8+ T-cells of which 7.8% were tetramer posi- 
tive. These results suggest hat bone marrow containing TCR- 
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